Mimenza-Alvarado A, Aguilar-Navarro S

Idioma: Español
Referencias bibliográficas: 31
Paginas: 375-383
Archivo PDF: 77.56 Kb.

RESUMEN

La neuropatía diabética representa la tercera complicación más frecuente de la diabetes mellitus. Cuando esta neuropatía se acompaña de dolor, requiere de un tratamiento específico. En el paciente anciano, el dolor tiene un enorme impacto en la calidad de vida, ya que se asocia a ansiedad, depresión y trastornos del dormir, lo que conlleva a una repercusión directa en la funcionalidad del paciente. Asimismo, se producen una serie de cambios a nivel del sistema nervioso periférico y central, que contribuyen a la cronicidad del proceso doloroso, y que terminan por afectar e impactar también en la calidad de vida del paciente anciano. Es fundamental, al decidir iniciar un tratamiento, conocer todos los aspectos farmacológicos relacionados con la farmacocinética y la farmacodinamia, que también están involucrados en el envejecimiento, ya que de esta manera, permitirán seleccionar el mejor fármaco para cada paciente. Esta revisión, pretende revisar conceptos fisiopatológicos relacionados con la neuropatía diabética de inicio en el anciano, así como las mejores alternativas de tratamiento.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Harati Y. Diabetic Neuropathies: Unanswered questions. Neurol Clin 2007; 25: 303-17.

2. Vinik AI, Strotmeyer ES, Nakave AA, et al. Diabetic neuropathy in older adults. Clin Geriatr Med 2008; 24: 407-35.

3. Barkin RL, Barkin SJ, Barkin DS. Pharmacotherapeutic Management of pain with a focus directed at the geriatric patient. Rheum Dis Clin N Am 2007; 33: 1-31.

4. Katz B, Helme RD. Pain problems in old age. In: Tallis R, Fillit H, Brocklehurst JC, editors. Brocklehurst´s textbook of geriatric medicine and gerontology. London: Harcourt Brace; 1998.

5. Bruckental P. Assessment pf pain in the elderly adult. Clin Geriatr Med 2008; 24: 213-36.

6. Nagda J, Bajwa ZH. In Warfieldn CA, Bajwa ZH. Principles and Practice of Pain Medicine. United States of America: McGraw-Hill; 2004.

7. Merskey H, Bogduk N. Classification of chronic pain. Seattle: IASP Press, 1994.

8. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain. Redefinition and a grading system for clinical and research purposes. Neurology 2008; 70: 1630-5.

9. Boulton AJM, Malik RA, Arezzo JC, et al. Diabetic somatic neuropathies. Diabetes care 2004; 27: 1458-86.

10. Unger J, Cole BE. Recognition and management of diabetic neuropathy. Prim Care Clin Office Pract 2007; 34: 887-913.

11. Ziegler D. Treatment of diabetic neuropathy and neuropathic pain. Diabetes care 2008; 31(Suppl 2): S255-S261.

12. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000; 288: 1765-8.

13. Woolf CF. Central sensitization. Uncovering the relation between pain and plasticity. Anesthesiology 2007; 106: 864-7.

14. Mendell JR, Sahenk Z. Painful sensory neuropathy. N Engl Med 2003; 348: 1243-55.

15. Mimenza AJ, Muñiz JC, Estañol B. Neuropatías dolorosas: fisiopatología y tratamiento. Rev Neurol 2004; 39: 364-70.

16. Bedlack RS, Edelman D, Gibbs JW, et al. APOE genotype is a risk factor for neuropathy severity in diabetic patients. Neurology 2003; 60: 1022-4.

17. Bedlack RS, Strittmatter WJ, MorgenlanderJC. Apolipoprotein E and neuromuscular disease. Arch Neurol 2000; 57: 1561-5.

18. Stephens JW, Dhamrait SS, Acharya J, et al. A common variant in the ACE gene is associated with peripheral neuropathy in women with type 2 diabetes mellitus. J Diabetes Complications 2006; 20: 317-21.

19. Sivenius K, Niskanen L, Voutilainen-Kaumisto R, et al. Aldose reductase gene polymorphisms and susceptibility to microvascular complications in type 2 diabetes. Diabet Med 2004; 21: 1325-33.

20. McCleane G. Pain perception in the elderly patient. Clin Geriatr Med 2008; 24: 203-11.

21. Verdu E, Ceballos D, Vilches JJ. Influence of aging on peripheral nerve function and regeneration. J Peripher Ner System 2000; 5: 191-208.

22. Gómez-Pérez FJ, Pérez Monteverde A, Nascimiento O, Aschner P, Tagle M, Fichtner K, et al. Gabapentin for the treatment of painful diabetic neuropathy: Titration to effect is superior to a commonly used fixed dose. BJ Diabet Vasc Dis 2004; 4(3): 173-8.

23. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus Guidelines: treatment planning and options. Mayo Clin Proc 2006; 81: S12-S26.

24. American Diabetes Association. Standars of medical care in diabetes- 2009. Diabetes Care 2009; 32(Suppl 1): S13-61.

25. Weiner D. Office management of chronic pain in the elderly. Am J Med 2007; 120: 306-15.

26. Freeman R, Durso-DeCruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy. Findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008; 31: 1448-54.

27. Backonja M, Beydoun A, Edwards R, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280: 1831-6.

28. Eisenberg E, Lurie Y, Braker C, et al. Lamotrigine reduced diabetic neuropathy: a randomized, controlled study. Neurology 2001; 57: 505-9.

29. Song XS, Huang ZJ, Song XJ. Thiamine suppresses thermal hyperalgesia, inhibits hyperexcitability and lessens alterations of sodium currents in injured, dorsal roort ganglion neurons in rats. Anesthesiology 2009; 110: 387-400.

30. Reyes GG, Caram SL, Medina SR,et al. Oral administration of B vitamins increases the antiallodynic effect of gabapentin in the rat. Proc West Pharmacol Soc 2004; 47: 76-9.

31. Medina SR, Morales FG, Espinoza RJ, et al. Treatment of diabetic neuropathic pain with gabapentin alone or combined with vitamin b complex. Preliminary results. Proc West Pharmacol Soc 2004; 47: 109-12.